Go to Client Portal
NAMSA

NAMSA ACQUIREs EUROPEAN-BASED MEDANEX CLINIC TO EXPAND EARLY-STAGE PRECLINICAL RESEARCH CAPABILITIES

TOLEDO, OHIO and BELGIUM – BUSINESSWIRE—MARCH 30, 2022NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its nearing acquisition of Medanex Clinic, a Belgium-based European preclinical research organization.

Founded in 2010, Medanex is focused on providing exceptional preclinical services to the medical device industry in Europe and across the globe. Their team of internationally renowned Cardiovascular surgeons and staff are well-known for guiding Clients through the preclinical study design pathway to achieve successful results. World-leading companies, as well as small innovative research groups, regulatory partner with Medanex for their outstanding Cardiovascular services and timely, efficacious study outcomes.

“NAMSA is very excited to expand its European preclinical services with the addition of Medanex,” said Dr. Christophe Berthoux, CEO of NAMSA. “Their robust preclinical capabilities and expertise, specifically in the Cardiovascular arena, will help enhance the NAMSA Client experience. We are pleased to partner with an organization that strongly shares our core values and drive to accelerate medical device development throughout the world,” Dr. Berthoux concluded.

As the global leader of the medical device testing industry, NAMSA has amassed the largest breadth and depth of therapeutic expertise and knowledge than any other preclinical development partner in industry. The organization’s preclinical research services provide support for all model types, treatments and implant requirements. NAMSA also provides Clients the benefit of full continuum development services, including regulatory, reimbursement, quality and clinical research services—proven to reduce timelines up to 30 percent over industry averages.

“Medanex is proud to become a part of the NAMSA family. With a similar vision to deliver world class expertise and exceptional service and resources to the medical device industry, we are ideally aligned. For 12 years, we’ve grown to become a trusted and respected partner for the most challenging surgical studies while remaining customer-oriented and striving for scientific excellence,” stated Medanex CEO, Hadewych Van Hauwermeiren. “With the complementary expertise and resources of NAMSA, we will serve our Clients in an even greater capacity and look forward to joining the world’s leading CRO for Cardiovascular research,” Van Hauwermeiren concluded.

The acquisition of Medanex Clinic increases NAMSA’s scale in Europe and growing global presence, now serving Clients in 20 locations across the Americas, Asia-Pacific and Europe.

The price and terms of the approaching transaction are undisclosed.

Leah Davidson, MA, MBA

Leah Davidson, MA, MBA

Leah has been with NAMSA since 2016 and currently serves as Senior Manager of Global Marketing Communications. She possesses 20 years' experience within the medical device, healthcare technology and non-profit industries and has worked in various marketing and communications capacities throughout her career. In her role at NAMSA, she is responsible for the development and implementation of brand strategies and marketing communications initiatives that help drive the organization's sales and organizational growth goals globally.